NVCRNovoCure Limited
$14.58+15% 1Y
$14.58
$10.0352 weeks$20.00
Latest close: back above its 200-day averageOct 9, 2026what changed →
The financials
NovoCure Limited by the numbers
NovoCure Limited (NVCR) reported revenue of $184M in Q2 2026 (quarter ended Jun 30, 2026), up 16% from the same quarter a year earlier. That came with a gross margin of 78% and net loss of $16M. For the full year FY2025, revenue was $655M (+8.3% year on year) and net income −$136M. Its largest region in Q2 2026 was United States at $103M, 62% of the disclosed total, well ahead of Germany at 14%. The next results filing is expected around Oct 29, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $184M | $159M | +16% |
| Gross profit | $142M | $117M | +21% |
| Operating income | −$11M | −$40M | n/a |
| Net income | −$16M | −$40M | n/a |
| Diluted EPS | −$0.13 | −$0.36 | n/a |
| Geographic | Revenue | Share |
|---|---|---|
| United States | $103M | 62% |
| Germany | $23M | 14% |
| France | $21M | 13% |
| Japan | $12M | 7.1% |
| China | $6.0M | 3.6% |
Business segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Jun 2026Total $165.4M (+4.4%)
China grew +30% year on yearUnited States +9.2% year on year
Segment Latestquarter on quarteryear on year
- United States$103.0M$103.0Mquarter on quarter +7.3%year on year +9.2%+7.3%+9.2%
- Germany$23.3M$23.3Mquarter on quarter -4.7%year on year +22%-4.7%+22%
- France$21.3M$21.3Mquarter on quarter -6.7%year on year +16%-6.7%+16%
- Japan$11.8M$11.8Mquarter on quarter +15%year on year +24%+15%+24%
- China$6.0M$6.0Mquarter on quarter +24%year on year +30%+24%+30%